In this episode of Inside Biotech, we sit down with Philip Sell, founder of Metaba, a biotech company focused on developing new approaches to combat drug-resistant infections, including tuberculosis.We dive into the founding story of Metaba, exploring the problem the company aims to solve and the scientific strategy behind its approach. Philip discusses the challenges of transitioning from a research-focused background to leading a startup, as well as the realities of building a biotech company from the ground up.
The conversation also highlights the global impact of tuberculosis, the growing threat of antibiotic resistance, and why developing new treatments is both urgent and complex. Philip shares his perspective on the future of infectious disease drug discovery and offers advice for scientists interested in entering the startup space.

Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!

To learn more about BCLA’s events and consulting visit our website.

Follow BCLA on LinkedIn

 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Daniel Arce, Bryan Jimenez, Danielle Luu, Stephanie Wu, Riley Elmer, Sanju Vardhan, Karishma Chhugani, Ethan Chung. Innehållet i podden är skapat av Daniel Arce, Bryan Jimenez, Danielle Luu, Stephanie Wu, Riley Elmer, Sanju Vardhan, Karishma Chhugani, Ethan Chung och inte av, eller tillsammans med, Poddtoppen.